Anaptysbio (ANAB) Cash & Equivalents Growth (3y) (2019 - 2026)

Anaptysbio (ANAB) Cash & Equivalents Growth (3y) (2019 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (3y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - 13.29%
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 10.63%
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -16.07%
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -8.88%
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Anaptysbio 1.55 Bn 1.27 Bn - 37.99%

Historic Data

Download Data
DateValue
Mar 31, 2026 37.99%
Dec 31, 2025 49.49%
Sep 30, 2025 23.33%
Jun 30, 2025 -14.83%
Mar 31, 2025 -16.00%
Dec 31, 2024 -37.15%
Sep 30, 2024 -17.10%
Jun 30, 2024 -39.98%
Mar 31, 2024 -42.62%
Dec 31, 2023 -47.63%
Sep 30, 2023 -49.90%
Jun 30, 2023 -45.80%
Mar 31, 2023 -16.99%
Dec 31, 2022 -25.29%
Sep 30, 2022 -31.59%
Jun 30, 2022 -21.20%
Mar 31, 2022 16.28%
Dec 31, 2021 63.42%
Sep 30, 2021 4.66%
Jun 30, 2021 79.91%